Cargando…

Stereotactic Body Radiation Therapy for Low- and Low-Intermediate-Risk Prostate Cancer: Is there a Dose Effect?

This study examines the efficacy and toxicity of two stereotactic body radiation therapy (SBRT) dose regimens for treatment of early prostate cancer. Forty-one patients treated with 35 Gy were matched with 41 patients treated with 36.25 Gy. Both patient groups received SBRT in five fractions over fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katz, Alan J., Santoro, Michael, Ashley, Richard, Diblasio, Ferdinand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2011
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356012/ https://www.ncbi.nlm.nih.gov/pubmed/22655249 http://dx.doi.org/10.3389/fonc.2011.00049

Ejemplares similares

Stereotactic body radiotherapy for organ-confined prostate cancer
por: Katz, Alan J, et al.
Publicado: (2010)

Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years
por: Katz, Alan J, et al.
Publicado: (2013)

Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer
por: Aghdam, Nima, et al.
Publicado: (2020)

Stereotactic Body Radiotherapy as Treatment for Organ Confined Low- and Intermediate-Risk Prostate Carcinoma, a 7-Year Study
por: Katz, Alan Jay, et al.
Publicado: (2014)

Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
por: Kataria, Shaan, et al.
Publicado: (2017)

Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma
por: Jeong, Bae-Kwon, et al.
Publicado: (2015)

Prostate-Specific Antigen Bounce Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Vu, Charles C., et al.
Publicado: (2014)

Low Incidence of Fatigue after Hypofractionated Stereotactic Body Radiation Therapy for Localized Prostate Cancer
por: Dash, Chiranjeev, et al.
Publicado: (2012)

A Phase II Study of Stereotactic Body Radiation Therapy for Low-Intermediate-High-Risk Prostate Cancer Using Helical Tomotherapy: Dose-Volumetric Parameters Predicting Early Toxicity
por: Macias, Victor A., et al.
Publicado: (2014)

Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel
por: Kundu, Palak, et al.
Publicado: (2022)

Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer
por: Gallagher, Lindsey, et al.
Publicado: (2023)

The Association of Radiation Dose With Overall Survival for Patients Treated With Prostate Stereotactic Body Radiation Therapy
por: Waters, Michael R, et al.
Publicado: (2023)

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer
por: Ahmed, Kamran A., et al.
Publicado: (2013)

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Janowski, Einsley-Marie, et al.
Publicado: (2015)

Intrafraction Prostate Motion Management During Dose-Escalated Linac-Based Stereotactic Body Radiation Therapy
por: Panizza, Denis, et al.
Publicado: (2022)

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Shah, Sarthak, et al.
Publicado: (2021)

Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective Trials
por: Quon, Harvey C., et al.
Publicado: (2016)

Gantry-Mounted Linear Accelerator–Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer
por: Dang, Audrey T., et al.
Publicado: (2019)

Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer
por: Blacksburg, Seth R., et al.
Publicado: (2020)

Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy
por: Carrasquilla, Michael, et al.
Publicado: (2021)

Stereotactic body radiotherapy with CyberKnife(®) System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial
por: Borzillo, Valentina, et al.
Publicado: (2023)

Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer
por: Sholklapper, Tamir N., et al.
Publicado: (2022)

The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups
por: Ricco, Anthony, et al.
Publicado: (2016)

Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer
por: Chen, Lily, et al.
Publicado: (2022)

Treating Low-Grade Myxofibrosarcoma With Stereotactic Body Radiation Therapy Using CyberKnife®
por: Mizumatsu, Shinichiro, et al.
Publicado: (2021)

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Cost-Effectiveness Results
por: Bijlani, Akash, et al.
Publicado: (2013)

Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
por: Kim, Hun Jung, et al.
Publicado: (2016)

Stereotactic Body Radiation Therapy for Prostate Cancer: Review of Experience of a Multicenter Phase I/II Dose-Escalation Study
por: Kim, D. W. Nathan, et al.
Publicado: (2014)

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience
por: Mercado, Catherine, et al.
Publicado: (2016)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
por: Ju, Andrew W, et al.
Publicado: (2013)

Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction
por: Repka, Michael C., et al.
Publicado: (2016)

Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer
por: Bhattasali, Onita, et al.
Publicado: (2013)

Focal Prostate Stereotactic Body Radiation Therapy With Correlative Pathological and Radiographic-Based Treatment Planning
por: Fredman, Elisha, et al.
Publicado: (2021)

Comparative Cost-Effectiveness of Stereotactic Body Radiation Therapy Versus Intensity-Modulated and Proton Radiation Therapy for Localized Prostate Cancer
por: Parthan, Anju, et al.
Publicado: (2012)

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
por: Kishan, Amar U., et al.
Publicado: (2019)

Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer
por: Oermann, Eric K, et al.
Publicado: (2011)

High versus low dose Stereotactic Body Radiation Therapy for hepatic metastases
por: Kok, Esther N.D., et al.
Publicado: (2019)

Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: A Ten-Year Analysis
por: Katz, Alan
Publicado: (2017)

Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy
por: Lei, Siyuan, et al.
Publicado: (2011)

Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer
por: Simhal, Rishabh K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b5vu46k5vol27d35fs2dl1lncv